| # | Drug | Count |
|---|---|---|
| 0 | AXICABTAGENE CILOLEUCEL | 9 |
| 1 | ANAKINRA | 8 |
| 2 | CYCLOPHOSPHAMIDE | 8 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 8 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 8 |
| 5 | FLUDARABINE PHOSPHATE | 8 |
| 6 | METHYLPREDNISOLONE SODIUM SUCCINATE | 8 |
| 7 | SILTUXIMAB | 8 |
| 8 | TOCILIZUMAB | 8 |
| 9 | BACILLUS CALMETTE-GUERIN | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SILTUXIMAB | 8 | 0.0123 |
| 1 | BACILLUS CALMETTE-GUERIN | 6 | 0.0034 |
| 2 | AXICABTAGENE CILOLEUCEL | 9 | 0.0009 |
| 3 | ANAKINRA | 8 | 0.0005 |
| 4 | FLUDARABINE PHOSPHATE | 8 | 0.0002 |
| 5 | METHYLPREDNISOLONE SODIUM SUCCINATE | 8 | 0.0002 |
| 6 | TOCILIZUMAB | 8 | 0.0001 |
| 7 | CYCLOPHOSPHAMIDE FOR INJECTION | 8 | 0.0000 |
| 8 | CYCLOPHOSPHAMIDE | 8 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-6 Antagonist [EPC] | 8 | 0.0123 |
| 1 | Live Attenuated Bacillus Calmette-Guerin Immunotherapy [EPC] | 6 | 0.0034 |
| 2 | CD19-directed Chimeric Antigen Receptor [EPC] | 9 | 0.0009 |
| 3 | Interleukin-1 Receptor Antagonist [EPC] | 8 | 0.0005 |
| 4 | Interleukin-6 Receptor Antagonist [EPC] | 8 | 0.0001 |
| 5 | Alkylating Drug [EPC] | 8 | 0.0000 |